CRMDCorMedix Inc.同业对比
CorMedix Inc. 与Pharmaceutical Preparations的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Pharmaceutical Preparations)| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRMD本股 | $604M#7 | 3.6x#2 | 1.3x#2 | 1.9x#2 | 617.0%#2 | 1009.4%#2 | 48.2%#1 | 35.4%#1 | — | — | -38.7%#15 | — |
| NGNE | $672M#1 | — | 3.1x#9 | — | -100.0%#14 | -20.2%#11 | — | -41.6%#9 | — | — | 89.6%#5 | — |
| IRWD | $672M#2 | 5.1x#3 | — | 2.3x#4 | -15.7%#10 | 2629.5%#1 | 33.3%#2 | — | 42.6%#1 | — | 217.6%#2 | — |
| VSTM | $665M#3 | — | 13.3x#10 | 21.5x#9 | 209.1%#4 | -60.3%#13 | -550.3%#10 | -419.1%#12 | — | — | -25.3%#13 | — |
| PHAT | $659M#4 | — | — | 3.8x#5 | 216.9%#3 | 33.8%#8 | -91.4%#7 | — | — | 4#1 | -28.9%#14 | — |
| ALT | $628M#5 | — | 1.3x#3 | 15324.2x#12 | 105.0%#6 | 7.3%#9 | -230461.0%#13 | -18.6%#7 | -21.1%#4 | — | -10.0%#12 | — |
| FBIOP | — | 6.7x#4 | — | — | 9.7%#8 | 76.2%#4 | -111.0%#8 | 22.5%#2 | — | — | 110.5%#3 | — |
| AQST | $605M#6 | — | — | 13.6x#8 | -22.6%#11 | -89.8%#14 | -159.5%#9 | — | — | — | -6.2%#11 | — |
| STTK | $599M#8 | — | 2.8x#8 | 599.2x#11 | -82.5%#13 | 35.3%#6 | -5150.8%#12 | -23.1%#8 | — | — | 233.5%#1 | — |
| CTMX | $588M#9 | — | 1.9x#6 | 7.7x#7 | -44.8%#12 | -154.5%#16 | -29.3%#5 | -5.7%#4 | -7.8%#3 | — | 35.7%#7 | — |
| ANNX | — | — | — | — | — | -49.6%#12 | — | -111.1%#11 | — | — | 58.1%#6 | — |
| ARVN | $541M#10 | 31.8x#6 | 1.0x#1 | 2.1x#3 | -0.3%#9 | 59.3%#5 | -45.1%#6 | -14.4%#6 | -25.3%#5 | — | 7.0%#10 | — |
| ASMB | $531M#11 | 21.0x#5 | 1.7x#5 | 7.3x#6 | 153.5%#5 | 84.8%#3 | -16.8%#4 | -2.0%#3 | -4.4%#2 | — | 22.9%#8 | — |
| OVID | $529M#12 | — | 2.5x#7 | 73.0x#10 | 1181.3%#1 | 34.1%#7 | -585.2%#11 | -8.3%#5 | — | — | 110.1%#4 | — |
| EOLS | $522M#13 | — | — | 1.8x#1 | 11.6%#7 | -2.4%#10 | -11.0%#3 | — | -40.5%#6 | 4#1 | 19.3%#9 | — |
| MPLT | $513M#14 | 0.3x#1 | 1.5x#4 | — | — | -107.7%#15 | — | -46.3%#10 | — | — | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-09-16。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议